Bexicaserin - Longboard Pharmaceuticals
Alternative Names: AN 352; LP-352Latest Information Update: 10 Dec 2025
At a glance
- Originator Longboard Pharmaceuticals
- Class 3-ring heterocyclic compounds; Amides; Antiepileptic drugs; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Yes - Dravet syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Developmental disabilities
Most Recent Events
- 06 Dec 2025 Long-term efficacy and adverse event data from a phase Ib/IIa PACIFIC in Developmental disabilities released by Lundbeck A/S
- 02 Dec 2025 Efficacy and adverse event data from a phase Ib/IIa PACIFIC in Developmental disabilities released by Longboard Pharmaceuticals
- 16 Oct 2025 Longboard Pharmaceuticals completes a Phase-I pharmacokinetics trials (In volunteers) in USA (PO) prior to May 2025